{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04879329",
            "orgStudyIdInfo": {
                "id": "RC48G001"
            },
            "secondaryIdInfos": [
                {
                    "id": "KEYNOTE-D78",
                    "type": "OTHER",
                    "domain": "Merck Sharp & Dohme LLC"
                },
                {
                    "id": "MK-3475-D78",
                    "type": "OTHER",
                    "domain": "Merck Sharp & Dohme LLC"
                },
                {
                    "id": "2022-500030-28",
                    "type": "REGISTRY",
                    "domain": "CTIS (EU)"
                }
            ],
            "organization": {
                "fullName": "Seagen Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2",
            "officialTitle": "A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-disitamab-vedotin-alone-or-with-pembrolizumab-in-urothelial-cancer-that-expresses"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-19",
            "studyFirstSubmitQcDate": "2021-05-07",
            "studyFirstPostDateStruct": {
                "date": "2021-05-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Seagen Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.\n\nParticipants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).\n\nIt will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease."
        },
        "conditionsModule": {
            "conditions": [
                "Urothelial Carcinoma"
            ],
            "keywords": [
                "Urothelial Cancer",
                "Bladder Cancer",
                "HER2 Mutations",
                "HER2 Overexpression",
                "HER2 Amplification",
                "RC48",
                "Seattle Genetics"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Cohorts A, B, C, and D will enroll simultaneously. Cohort E will begin enrollment after Cohort D participants have completed the DLT evaluation period.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 332,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort A - DV monotherapy for HER2-positive tumor types",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin monotherapy",
                    "interventionNames": [
                        "Drug: disitamab vedotin"
                    ]
                },
                {
                    "label": "Cohort B - DV monotherapy for HER2-low tumor types",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin monotherapy",
                    "interventionNames": [
                        "Drug: disitamab vedotin"
                    ]
                },
                {
                    "label": "Cohort C - Non-randomized combination therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin + pembrolizumab",
                    "interventionNames": [
                        "Drug: disitamab vedotin",
                        "Drug: pembrolizumab"
                    ]
                },
                {
                    "label": "Cohort C - Randomized combination therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin + pembrolizumab",
                    "interventionNames": [
                        "Drug: disitamab vedotin",
                        "Drug: pembrolizumab"
                    ]
                },
                {
                    "label": "Cohort C - Randomized monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin monotherapy",
                    "interventionNames": [
                        "Drug: disitamab vedotin"
                    ]
                },
                {
                    "label": "Cohort D - DV monotherapy (Japan only)",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin monotherapy",
                    "interventionNames": [
                        "Drug: disitamab vedotin"
                    ]
                },
                {
                    "label": "Cohort E - DV combination therapy (Japan only)",
                    "type": "EXPERIMENTAL",
                    "description": "Disitamab vedotin + pembrolizumab",
                    "interventionNames": [
                        "Drug: disitamab vedotin",
                        "Drug: pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "disitamab vedotin",
                    "description": "Given into the vein (IV; intravenous) every 2 weeks.",
                    "armGroupLabels": [
                        "Cohort A - DV monotherapy for HER2-positive tumor types",
                        "Cohort B - DV monotherapy for HER2-low tumor types",
                        "Cohort C - Non-randomized combination therapy",
                        "Cohort C - Randomized combination therapy",
                        "Cohort C - Randomized monotherapy",
                        "Cohort D - DV monotherapy (Japan only)",
                        "Cohort E - DV combination therapy (Japan only)"
                    ],
                    "otherNames": [
                        "RC48-ADC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "pembrolizumab",
                    "description": "Given by IV on Day 1 of each 6-week cycle.",
                    "armGroupLabels": [
                        "Cohort C - Non-randomized combination therapy",
                        "Cohort C - Randomized combination therapy",
                        "Cohort E - DV combination therapy (Japan only)"
                    ],
                    "otherNames": [
                        "KEYTRUDA\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, and C)",
                    "description": "The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1",
                    "timeFrame": "Duration of treatment; approximately 2 years"
                },
                {
                    "measure": "Incidence of adverse events (AEs) (Cohorts D and E)",
                    "description": "Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Incidence of dose alterations (Cohorts D and E)",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Incidence of laboratory abnormalities (Cohorts D and E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Incidence of electrocardiogram (ECG) abnormalities (Cohorts D and E)",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Change from baseline of left ventricular ejection fraction (LVEF) (Cohorts D and E)",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Pharmacokinetic (PK) parameter - Area under the curve (AUC) (Cohorts D and E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter - Maximum concentration (Cmax) (Cohorts D and E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter - Time to maximum concentration (Tmax) (Cohorts D and E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter - Trough concentration (Ctrough) (Cohorts D and E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "cORR per RECIST v1.1 by investigator assessment (Cohorts A, B, and C)",
                    "description": "The proportion of participants with confirmed CR or PR according to RECIST v1.1",
                    "timeFrame": "Duration of treatment; approximately 2 years"
                },
                {
                    "measure": "Confirmed Duration of Response (DOR) per RECIST v1.1 by BICR (Cohorts A, B, and C)",
                    "description": "The time from first documentation of objective tumor response (confirmed CR or PR) to the first documentation of tumor progression per RECIST v1.1 or death due to any cause.",
                    "timeFrame": "From start of treatment to completion of response assessment; approximately 2 years"
                },
                {
                    "measure": "Confirmed DOR per RECIST v1.1 by investigator assessment (Cohorts A, B, and C)",
                    "description": "The time from first documentation of objective tumor response (confirmed CR or PR) to the first documentation of tumor progression per RECIST v1.1 or death due to any cause.",
                    "timeFrame": "From start of treatment to completion of response assessment; approximately 2 years"
                },
                {
                    "measure": "Progression-free survival (PFS) per RECIST v1.1 by BICR (Cohorts A, B, and C)",
                    "description": "The time from the start of study treatment or randomization (if applicable) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.",
                    "timeFrame": "From start of treatment to completion of response assessment; approximately 2 years"
                },
                {
                    "measure": "PFS per RECIST v1.1 by investigator assessment (Cohorts A, B, and C)",
                    "description": "The time from the start of study treatment or randomization (if applicable) to the first documentation of disease progression per RECIST v1.1 or death due to any cause.",
                    "timeFrame": "From start of treatment to completion of response assessment; approximately 2 years"
                },
                {
                    "measure": "Disease control rate (DCR) per RECIST v1.1 by BICR (Cohorts A, B, and C)",
                    "description": "The proportion of participants who have achieved objective response (confirmed CR or PR as per RECIST v1.1 criteria) or stable disease (SD) lasting at least 5 weeks.",
                    "timeFrame": "From start of treatment to completion of response assessment; approximately 2 years"
                },
                {
                    "measure": "DCR per RECIST v1.1 by investigator (Cohorts A, B, and C)",
                    "description": "The proportion of participants who have achieved objective response (confirmed CR or PR as per RECIST v 1.1 criteria) or SD lasting at least 5 weeks.",
                    "timeFrame": "From start of treatment to completion of response assessment; approximately 2 years"
                },
                {
                    "measure": "Overall survival (OS) (Cohorts A, B, and C)",
                    "description": "The time from start of study treatment or randomization (if applicable) to the date of death due to any cause.",
                    "timeFrame": "Duration of study; approximately 3 years"
                },
                {
                    "measure": "Incidence of adverse events (AEs) (Cohorts A, B, and C)",
                    "description": "Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Incidence of dose alterations (Cohorts A, B, and C)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Incidence of laboratory abnormalities (Cohorts A, B, and C)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Incidence of ECG abnormalities (Cohorts A, B, and C)",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Change from baseline of LVEF (Cohorts A, B, and C)",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "PK parameter - AUC (Cohorts A, B, and C)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter - Cmax (Cohorts A, B, and C)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter - Tmax (Cohorts A, B, and C)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter - Ctrough (Cohorts A, B, and C)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "PK parameter of pembrolizumab - Cmax (Cohort E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "Incidence of anti-drug antibodies (ADAs) against disitamab vedotin (All Cohorts)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "Incidence of anti-drug antibodies (ADAs) against pembrolizumab (Cohorts C and E)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                },
                {
                    "measure": "Incidence of neutralizing antibodies (NABs) against disitamab vedotin (All Cohorts)",
                    "description": "To be summarized using descriptive statistics.",
                    "timeFrame": "Through 30-37 days following the last dose of DV; up to approximately 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nCohorts A and B\n\n* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra\n* Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy\n* At least one measurable lesion by investigator assessment based on RECIST version 1.1.\n* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\nCohort C\n\n* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra\n* No prior systemic therapy for LA/mUC\n\n  * Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy\n* At least one measurable lesion by investigator assessment based on RECIST v1.1.\n* Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation\n* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample\n* ECOG performance status of 0, 1, or 2\n\nCohort D\n\n* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra\n* Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC:\n\n  * a. One prior line of platinum-containing chemotherapy.\n  * b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment.\n  * c. Prior enfortumab vedotin therapy.\n* At least one measurable lesion by investigator assessment based on RECIST v1.1.\n* ECOG performance status of 0 or 1\n\nCohort E\n\n* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra\n* No prior systemic therapy for LA/mUC\n\n  * Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy.\n* At least one measurable lesion by investigator assessment based on RECIST v1.1.\n* Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation\n* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample\n* ECOG performance status of 0 or 1\n\nExclusion Criteria:\n\nCohorts A and B\n\n* Known hypersensitivity to disitamab vedotin or any of their components\n* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B)\n* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)\n* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy\n* Major surgery that has not fully recovered within 4 weeks prior to dose administration\n* Peripheral sensory or motor neuropathy \u2265 Grade 2 at baseline\n\nCohort C\n\n* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components\n* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C)\n* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)\n* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy\n* Major surgery that has not fully recovered within 4 weeks prior to dose administration\n* Peripheral sensory or motor neuropathy \u2265 Grade 2 at baseline\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug\n* Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded.\n\nCohort D\n\n* Known hypersensitivity to disitamab vedotin or any of their components\n* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D)\n* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)\n* Prior HER2-directed therapy\n* Any prior history of \u2265 Grade 3 non-hematological AEs related to prior therapy\n* Major surgery that has not fully recovered within 4 weeks prior to dose administration\n* Peripheral sensory or motor neuropathy \u2265 Grade 1 at baseline\n\nCohort E\n\n* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components\n* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort E)\n* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)\n* Any prior history of \u2265 Grade 3 non-hematological AEs related to prior therapy\n* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy\n* Major surgery that has not fully recovered within 4 weeks prior to dose administration\n* Peripheral sensory or motor neuropathy \u2265 Grade 1 at baseline\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug\n\nThere are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Seagen Trial Information Support",
                    "role": "CONTACT",
                    "phone": "866-333-7436",
                    "email": "clinicaltrials@seagen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Monitor",
                    "affiliation": "Seagen Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Banner MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Gilbert",
                    "state": "Arizona",
                    "zip": "85234",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Isaac Bowman",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.35283,
                        "lon": -111.78903
                    }
                },
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Abhishek Tripathi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "University of California Los Angeles Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Alexandra Drakaki",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California Irvine Medical Center",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Nataliya Mar",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "Kaiser Permanente Southern California",
                    "status": "RECRUITING",
                    "city": "Riverside",
                    "state": "California",
                    "zip": "92505",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Helen Moon",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.95335,
                        "lon": -117.39616
                    }
                },
                {
                    "facility": "University of California, San Francisco | HDFCCC - Hematopoietic Malignancies",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Vadim Koshkin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Colorado Health Memorial Hospital",
                    "status": "COMPLETED",
                    "city": "Colorado Springs",
                    "state": "Colorado",
                    "zip": "80909",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.83388,
                        "lon": -104.82136
                    }
                },
                {
                    "facility": "Florida Cancer Specialists - South Region",
                    "status": "RECRUITING",
                    "city": "Fort Myers",
                    "state": "Florida",
                    "zip": "33901",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Amir Harandi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.62168,
                        "lon": -81.84059
                    }
                },
                {
                    "facility": "Florida Cancer Specialists - Panhandle",
                    "status": "RECRUITING",
                    "city": "Tallahassee",
                    "state": "Florida",
                    "zip": "32308",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Pareshkumar Patel",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.43826,
                        "lon": -84.28073
                    }
                },
                {
                    "facility": "H. Lee Moffitt Cancer Center and Research Institute",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Rohit Jain",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Florida Cancer Specialists - East West Palm Beach, FL (SCRI)",
                    "status": "RECRUITING",
                    "city": "West Palm Beach",
                    "state": "Florida",
                    "zip": "33401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Barry Berman",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.71534,
                        "lon": -80.05337
                    }
                },
                {
                    "facility": "Northwest Georgia Oncology Centers, P.C.",
                    "status": "RECRUITING",
                    "city": "Marietta",
                    "state": "Georgia",
                    "zip": "30060",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Steve McCune",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.9526,
                        "lon": -84.54993
                    }
                },
                {
                    "facility": "University of Chicago Medical Center",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Peter H O'Donnell",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Henry Ford Health System",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Clara Hwang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute / Wayne State University",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Elisabeth Heath",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Cancer and Hematology Centers of Western Michigan / Spectrum Health Butterworth Campus",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Eric Batts, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Comprehensive Cancer Centers of Nevada",
                    "status": "RECRUITING",
                    "city": "Las Vegas",
                    "state": "Nevada",
                    "zip": "89169",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Oscar B Goodman Jr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.17497,
                        "lon": -115.13722
                    }
                },
                {
                    "facility": "North Shore Center for Advanced Medicine Monter Cancer Center / North Shore University Hospital",
                    "status": "RECRUITING",
                    "city": "Lake Success",
                    "state": "New York",
                    "zip": "11042",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Thomas P Bradley",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.77066,
                        "lon": -73.71763
                    }
                },
                {
                    "facility": "New York University (NYU) Cancer Institute",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Scot Niglio",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Mount Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Matthew Galsky",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Gopakumar Iyer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SUNY Upstate Medical University",
                    "status": "COMPLETED",
                    "city": "Syracuse",
                    "state": "New York",
                    "zip": "13210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.04812,
                        "lon": -76.14742
                    }
                },
                {
                    "facility": "Levine Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Earle Burgess",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "University Hospitals Cleveland Medical Center",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Jason Robert Brown",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Oklahoma University at Stephenson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Adanma Ayanambakkam",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Oregon Health and Science University",
                    "status": "COMPLETED",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "University of Tennessee",
                    "status": "RECRUITING",
                    "city": "Knoxville",
                    "state": "Tennessee",
                    "zip": "37920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Saikrishna Gadde",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.96064,
                        "lon": -83.92074
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center / University of Texas",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030-4095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Matthew T Campbell",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute/University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sumati Gupta",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Inova Schar Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Jeanny B Aragon-Ching, MD, F.A.C.P.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Evan Yu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Medical College of Wisconsin (Milwaukee)",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seagen Trial Information Support",
                            "role": "CONTACT",
                            "phone": "866-333-7436",
                            "email": "clinicaltrials@seagen.com"
                        },
                        {
                            "name": "Ariel Nelson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Centro de Oncologia e Investigacion de Buenos Aires (COIBA)",
                    "status": "RECRUITING",
                    "city": "Berazategui",
                    "state": "Other",
                    "zip": "B1884BBF",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Mirta Varela",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.76531,
                        "lon": -58.21278
                    }
                },
                {
                    "facility": "Hospital Aleman (HA) Deutsches Hospital",
                    "status": "RECRUITING",
                    "city": "Buenos Aires",
                    "state": "Other",
                    "zip": "1118",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Gabriela Gatica",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Hospital Sirio Libanes",
                    "status": "RECRUITING",
                    "city": "Caba",
                    "state": "Other",
                    "zip": "1425",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Hernan Cutuli",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Instituto Alexander Fleming",
                    "status": "RECRUITING",
                    "city": "Ciudad Autonoma Buenos Aires",
                    "state": "Other",
                    "zip": "C1426ANZ",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Juan Pablo Sade",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Fundacion Cenit",
                    "status": "RECRUITING",
                    "city": "Caba",
                    "zip": "1125",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Guillermo Luis Lerzo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Clinica Viedma",
                    "status": "RECRUITING",
                    "city": "Viedma",
                    "zip": "R8500 JYJ",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Ruben Kowalyszyn",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -40.81345,
                        "lon": -62.99668
                    }
                },
                {
                    "facility": "Lyell McEwin Hospital",
                    "status": "RECRUITING",
                    "city": "Elizabeth Vale",
                    "state": "Other",
                    "zip": "5112",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Mark McGregor",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.74857,
                        "lon": 138.66819
                    }
                },
                {
                    "facility": "Peninsula and South East Oncology",
                    "status": "RECRUITING",
                    "city": "Frankston",
                    "state": "Other",
                    "zip": "3199",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Sanjeev Sewak",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -38.14458,
                        "lon": 145.12291
                    }
                },
                {
                    "facility": "Mater Cancer Care Centre",
                    "status": "RECRUITING",
                    "city": "South Brisbane",
                    "state": "Other",
                    "zip": "4101",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Niara Oliveira",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.48034,
                        "lon": 153.02049
                    }
                },
                {
                    "facility": "Royal North Shore Hospital",
                    "status": "RECRUITING",
                    "city": "St Leonards",
                    "state": "Other",
                    "zip": "2065",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Laurence Krieger, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.82344,
                        "lon": 151.19836
                    }
                },
                {
                    "facility": "Princess Alexandra Hospital",
                    "status": "RECRUITING",
                    "city": "Woolloongabba",
                    "state": "Other",
                    "zip": "4102",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Aaron R. Hansen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.48855,
                        "lon": 153.03655
                    }
                },
                {
                    "facility": "Macquarie University Hospital",
                    "status": "RECRUITING",
                    "city": "New South Whales",
                    "zip": "2109",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Alison Zhang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ]
                },
                {
                    "facility": "Algemeen Ziekenhuis Maria Middelares",
                    "status": "RECRUITING",
                    "city": "Gent",
                    "state": "Other",
                    "zip": "9000",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Christof Vulsteke",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.05,
                        "lon": 3.71667
                    }
                },
                {
                    "facility": "CHU UCL Namur-Site de Saint Elisabeth",
                    "status": "RECRUITING",
                    "city": "Namur",
                    "state": "Other",
                    "zip": "5000",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Vincent Vanhaudenarde",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.4669,
                        "lon": 4.86746
                    }
                },
                {
                    "facility": "Tom Baker Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Calgary",
                    "state": "Alberta",
                    "zip": "T2N 4N2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 51.05011,
                        "lon": -114.08529
                    }
                },
                {
                    "facility": "British Columbia Cancer Agency - Vancouver Centre",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V5Z4E6",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Bernhard Eigl",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "CancerCare Manitoba",
                    "status": "RECRUITING",
                    "city": "Winnipeg",
                    "state": "Manitoba",
                    "zip": "R3E 0V9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Joel Gingerich",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.8844,
                        "lon": -97.14704
                    }
                },
                {
                    "facility": "Jewish General Hospital",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "April Rose, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Centre hospitalier universitaire de Sherbrooke (CHUS)",
                    "status": "RECRUITING",
                    "city": "Sherbrooke",
                    "state": "Quebec",
                    "zip": "J1H 5N4",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Michel Pavic",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.40008,
                        "lon": -71.89908
                    }
                },
                {
                    "facility": "Centro de Estudios Clinicos IC La Serena Research",
                    "status": "RECRUITING",
                    "city": "La Serena",
                    "state": "Other",
                    "zip": "1720430",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Luisa Morales Galindo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -29.90453,
                        "lon": -71.24894
                    }
                },
                {
                    "facility": "Pontificia Universidad Catolica De Chile Santiago",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Other",
                    "zip": "7770177",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Carolina Ibanez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Instituto Oncologico Fundacion Arturo Lopez Perez (FALP)",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Other",
                    "zip": "Providencia",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Pamela Salman",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Rambam Health Corp.",
                    "status": "RECRUITING",
                    "city": "Haifa",
                    "state": "Other",
                    "zip": "3109601",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Avivit Pe'er",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81841,
                        "lon": 34.9885
                    }
                },
                {
                    "facility": "Rabin Medical Center",
                    "status": "RECRUITING",
                    "city": "Petach Tikva",
                    "state": "Other",
                    "zip": "49414",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Victoria Neiman",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08707,
                        "lon": 34.88747
                    }
                },
                {
                    "facility": "Sheba Medical Center",
                    "status": "RECRUITING",
                    "city": "Ramat Gan",
                    "state": "Other",
                    "zip": "52621",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Michal Sarfaty",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                },
                {
                    "facility": "Tel Aviv Sourasky Medical Center",
                    "status": "RECRUITING",
                    "city": "Tel Aviv",
                    "state": "Other",
                    "zip": "64239",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "David Sarid",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East",
                    "status": "RECRUITING",
                    "city": "Kashiwa-shi",
                    "state": "Other",
                    "zip": "277-8577",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Nobuaki Matsubara",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.86224,
                        "lon": 139.97732
                    }
                },
                {
                    "facility": "Osaka International Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Osaka",
                    "state": "Other",
                    "zip": "541-8567",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Masashi Nakayama",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.69374,
                        "lon": 135.50218
                    }
                },
                {
                    "facility": "Sapporo Medical University Hospital",
                    "status": "RECRUITING",
                    "city": "Sapporo",
                    "state": "Other",
                    "zip": "060-8543",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Naoya Masumori",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.06667,
                        "lon": 141.35
                    }
                },
                {
                    "facility": "Osaka University Hospital",
                    "status": "RECRUITING",
                    "city": "Suita-shi",
                    "state": "Other",
                    "zip": "565-0871",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Atsunari Kawashima",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.76143,
                        "lon": 135.51567
                    }
                },
                {
                    "facility": "Tokushima University Hospital",
                    "status": "RECRUITING",
                    "city": "Tokushima",
                    "state": "Other",
                    "zip": "770-8503",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Masayuki Takahashi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.06667,
                        "lon": 134.56667
                    }
                },
                {
                    "facility": "The Cancer Institute Hospital of JFCR",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "state": "Other",
                    "zip": "135-8550",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Takeshi Yuasa",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "Hospital de la Santa Creu i Sant Pau",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "state": "Other",
                    "zip": "08041",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Jose Pablo Maroto Rey",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center - Madrid",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "state": "Other",
                    "zip": "28033",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Enrique Grande Pulido",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitari Parc Tauli",
                    "status": "RECRUITING",
                    "city": "Sabadell",
                    "state": "Other",
                    "zip": "08208",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Teresa Bonfill",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.54329,
                        "lon": 2.10942
                    }
                },
                {
                    "facility": "Hospital Universitario Marques de Valdecilla",
                    "status": "RECRUITING",
                    "city": "Santander",
                    "state": "Other",
                    "zip": "39008",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Ignacio Duran Martinez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.46472,
                        "lon": -3.80444
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen del Rocio",
                    "status": "RECRUITING",
                    "city": "Seville",
                    "state": "Other",
                    "zip": "41013",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Begona Perez Valderrama",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                },
                {
                    "facility": "The Clatterbridge Cancer Centre NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Bebington",
                    "state": "Other",
                    "zip": "CH63 4JY",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Joachim Chan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.35,
                        "lon": -3.01667
                    }
                },
                {
                    "facility": "Cambridge University Hospitals NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Cambridge",
                    "state": "Other",
                    "zip": "CB2 0QQ",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Danish Mazhar",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.2,
                        "lon": 0.11667
                    }
                },
                {
                    "facility": "NHS Greater Glasgow and Clyde (NHSGGC) - The Beatson West of Scotland Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Glasgow",
                    "state": "Other",
                    "zip": "G12 0Yn",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Robert Jones",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 55.86515,
                        "lon": -4.25763
                    }
                },
                {
                    "facility": "Barts Health NHS Trust Saint Bartholomews Hospital",
                    "status": "RECRUITING",
                    "city": "London",
                    "state": "Other",
                    "zip": "EC1A 7BE",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Thomas Powles",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Guys and St Thomas Hospital",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SE1 7EH",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Kate Smith",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002295",
                    "term": "Carcinoma, Transitional Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "asFound": "Urothelial Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "asFound": "Urothelial Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "C000722994",
                    "term": "Disitamab vedotin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M240270",
                    "name": "Disitamab vedotin",
                    "asFound": "Adebrelimab",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}